Anti-dbi/acbp antibody

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Agence Nationale de la Recherche and 3 more

Animals1

Outcomes

CDKN1A expression

downin mice1

1 study

Anti-dbi/acbp antibody decreases CDKN1A expression in mice.
“anti-DBI/ACBP reduces expression of the senescence marker CDKN1A/p21 (cyclin dependent kinase inhibitor 1A) in cardiomyocytes and hepatocytes.”
Animalscardiac and hepatic aging modelsmonoclonal antibodiescardiomyocytes and hepatocytes
Pathological aging is alleviated by neutralization of the autophagy-repressive tissue hormone DBI/ACBP
Autophagy20 Aug 2025

Latest

Autophagy20 Aug

Pathological aging is alleviated by neutralization of the autophagy-repressive tissue hormone DBI/ACBP

Experiments in miceInterventions

Paper

Anti-dbi/acbp antibody

Outcomes

Latest

Pathological aging is alleviated by neutralization of the autophagy-repressive tissue hormone DBI/ACBP

Related